Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immunological tolerance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    60 result(s) found for: Immunological tolerance. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-001709-26 Sponsor Protocol Number: IMS012012 Start Date*: 2012-06-28
    Sponsor Name:Sevapharma,a.s.
    Full Title: Randomized, double-blind, placebo-controlled clinical trial of Immodin immunological efficacy in healthy adult volunteers.
    Medical condition: Immunological efficacy, in healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10021422 Immune status LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002802-34 Sponsor Protocol Number: Sandoz/OMNI/F/01/03 Start Date*: 2015-07-03
    Sponsor Name:Sandoz SAS
    Full Title: Multicentre study to evaluate the efficacy and safety of a liquid formulation of recombinant growth hormone, Omnitrope® 3.3mg/mL, in the treatment of pre-pubertal children of small stature sufferin...
    Medical condition: Small stature secondary to growth hormone insufficiency deficiency
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-015523-91 Sponsor Protocol Number: ENM-EA-011 Start Date*: 2010-01-21
    Sponsor Name:Medizinische Universiätsklinik Graz, Abteilung für Endokrinologie und Nuklearmedizin
    Full Title: Placebo controlled study on effects of vitamin D supplementation in healthy women and men on immunological, endocrine and metabolic parameters
    Medical condition: healthy volunteers. The intended indication for the investigated product is prevention and treatment of immunological (e.g. type 1 diabetes), endocrine (e.g. endocrine hypertension), metabolic (e.g...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002571-16 Sponsor Protocol Number: MBP8298-01 Amendment 04 Start Date*: 2007-06-29
    Sponsor Name:BioMS Technology Corp
    Full Title: A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis.
    Medical condition: Secondary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) FI (Completed) DK (Completed) ES (Completed) EE (Completed) NL (Completed) LT (Prematurely Ended) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000256-26 Sponsor Protocol Number: Start Date*: 2009-02-16
    Sponsor Name:Queen Mary, University of London
    Full Title: An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonβ-1a (IFNβ-1a, Rebif®) therapy in the induction of tolerance to IFNβ in MS patients with neu...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016029-32 Sponsor Protocol Number: ITI-CE-PR Start Date*: 2010-02-25
    Sponsor Name:STRUTTURA SEMPLICE GESTIONE-ORG.-FUNZ. HUB EMOFILIA
    Full Title: MECHANISM OF ACTION AND EFFICACY OF AN ALTERNATIVE IMMUNOTOLERANCE REGIMEN BASED ON MODULATION OF IMMUNE RESPONSES: A NEW CHANCE FOR HAEMOPHILIA PATIENTS WITH REFRACTORY INHIBITORS ?
    Medical condition: Haemophilic patients, with high responding inhibitor (>5 BU/ml), in whom previous ITI failed and who undergo the second line ITI protocol
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016080 PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000608-39 Sponsor Protocol Number: 21-ItolDC-028-01 Start Date*: 2022-09-20
    Sponsor Name:Idogen AB
    Full Title: An open-label, multi-center, first in human, phase 1/2a trial to evaluate the safety and preliminary efficacy of autologous tolerogenic dendritic cells ex vivo loaded with recombinant Factor VIII (...
    Medical condition: Treatment of patients with Hemophilia A who have developed inhibitory antibodies to clotting Factor VIII and have failed Immune Tolerance Induction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    Population Age: Adults Gender: Male
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023103-94 Sponsor Protocol Number: 002:CD40L Start Date*: 2011-07-04
    Sponsor Name:Uppsala University
    Full Title: PHASE I/IIa AdCD40L IMMUNOGENE THERAPY FOR MALIGNANT MELANOMA PATIENTS WITH DISSEMINATED DISEASE
    Medical condition: malignant melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004983-37 Sponsor Protocol Number: FFIS-INM-2017-04 Start Date*: 2018-10-16
    Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
    Full Title: Multicenter, randomized, prospective study to establish the clinical efficacy and the mechanisms of tolerance following immunosuppression withdrawal in liver transplantation
    Medical condition: Hepatic transplant
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018901-12 Sponsor Protocol Number: ADPP-002ENM-DA-017 Start Date*: 2010-10-20
    Sponsor Name:Medical University Graz, Department of Internal Medicine, Div. Endocrinology and Metabolism [...]
    1. Medical University Graz, Department of Internal Medicine, Div. Endocrinology and Metabolism
    2.
    Full Title: Placebo controlled study on effects of vitamin D supplementation in type 1 diabetic subjects on immunological, endocrine and metabolic parameters: Step 2 of the Austrian Diabetes Prevention Program...
    Medical condition: To evaluate whether vitamin D supplementation in type 1 diabetic subjects significantly alters the proportion of regulatory T-cells of all circulating CD4 positive T-cells.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004419-35 Sponsor Protocol Number: GN13RH410 Start Date*: 2015-03-18
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Inhibition of Co-Stimulation in Rheumatoid Arthritis
    Medical condition: Rheumatoid Arthritis: patients who are dual ACPA and HLA-DR4 positive
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2022-002385-32 Sponsor Protocol Number: APHP211057 Start Date*: 2022-08-31
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Immediate versus delayed treatment with azathioprine or rituximab in anti-myelin oligodendrocytes glycoprotein (anti-MOG) antibodies associated acute demyelinating syndromes in children: a randomiz...
    Medical condition: myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD)
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000410-18 Sponsor Protocol Number: 061002 Start Date*: 2011-05-05
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A PHASE 3b CLINICAL STUDY TO ASSESS WHETHER REGULAR ADMINISTRATION OF ADVATE IN THE ABSENCE OF IMMUNOLOGICAL DANGER SIGNALS REDUCES THE INCIDENCE RATE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS...
    Medical condition: Prevention of inhibitor formation, and immune tolerance induction in patients with severe and moderately severe hemophilia A by early and low-dose prophylactic ADVATE therapy
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male
    Trial protocol: AT (Prematurely Ended) DE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) BG (Completed) ES (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) PL (Prematurely Ended) PT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000975-18 Sponsor Protocol Number: M13-397 Start Date*: 2012-09-26
    Sponsor Name:Abbott Laboratories GmbH
    Full Title: Open-label, Randomized, Parallel-Group, Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects with Nonalcoholic Steatohepatitis (NASH) and no...
    Medical condition: Nonalcoholic Steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002735-23 Sponsor Protocol Number: IPROTECT1 Start Date*: 2013-12-04
    Sponsor Name:InnaVirVax SA
    Full Title: Assessment of the therapeutic properties of the VAC-3S immunoprotective vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. A European multicenter, r...
    Medical condition: Chronically infected HIV-1 patients under viral control on Anti-Retroviral therapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004262-34 Sponsor Protocol Number: MM09-SIT-023 Start Date*: 2020-04-28
    Sponsor Name:Inmunotek, S.L.
    Full Title: Randomized, placebo-controlled, prospective clinical trial of efficacy and safety for the treatment of rhinitis/rhinoconjunctivitis and asthma against a mixture of Dermatophagoides pteronyssinus an...
    Medical condition: House dust mites allergy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001435-27 Sponsor Protocol Number: CHUBX2020/12 Start Date*: 2020-04-10
    Sponsor Name:CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC
    Full Title: Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety of several experimental treat...
    Medical condition: severe acute respiratory syndrome coronavirus 2(SARS-CoV 2)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001429-16 Sponsor Protocol Number: HORA-PDE6B-001 Start Date*: 2017-07-28
    Sponsor Name:HORAMA SA
    Full Title: Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients Harboring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression.
    Medical condition: Retinitis Pigmentosa
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000567-25 Sponsor Protocol Number: 100063 Start Date*: 2005-08-10
    Sponsor Name:NUMICO RESEARCH BV
    Full Title: Tolerance and immunological response in HIV seropositive individuals after NR100063 supplementation
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    6.1 10021881 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001393-19 Sponsor Protocol Number: 003:TCELL Start Date*: 2014-04-08
    Sponsor Name:Uppsala university
    Full Title: CD19-targeting 3rd generation CAR T cells for refractory B cell malignancy - a phase I/IIa trial.
    Medical condition: CD19+ B cell lymphoma or leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 15:15:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA